Last reviewed · How we verify

NCT06784687

Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease

Completed Last updated 20 January 2025
What this trial tests

trial in Congenital Heart Disease in 2,376 participants. Completed in 31 December 2021.

Timeline
1 August 2021
Primary endpoint
30 September 2021
31 December 2021

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,376
Start date1 August 2021
Primary completion30 September 2021
Estimated completion31 December 2021
Sites1 location across Italy

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Eligibility, any sex, with Congenital Heart Disease or Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study, drug-free, cross-sectional, single-center is to describe the incidence and characteristics of the clinical course and any short- and medium-term complications of patients with congenital heart disease of medical interest, and pediatric patients with cardiomyopathy, arrhythmic pathology or pulmonary arterial hypertension who have been affected by Sars-Cov-2 disease. The secondary objective of the study is to identify risk factors for the development of moderate-severe forms of COVID-19 disease in the study population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06784687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing